Atorvastatin

Atorvastatin, marketed under the trade name Lipitor among others, is a member of the drug class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease.

Atorvastatin

Atorvastatin; Cardyl; Tozalip; Xavator

Unitor (10mg), Stator (40mg), Lorisk (10mg/160mg/5mg), Etovas (20mg), Mactor (10mg), Genxvast (10mg), Noklot-CV, Atornet (5mg), Nustat (10mg), Atorva (80mg), Atarp (20mg), Zenolip (10mg), Redustat Plus (10mg/200m

7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate

• Absorption: Oral
• Distribution: 99% protein binding
• Metabolism: Hepatic
• Excretion: Feces

Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this result in a subsequent decrease in hepatic cholesterol levels. A decreased hepatic cholesterol level stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.

Initially, 10 or 20 mg/day may increase at 4-weekly intervals. 

Coronary heart disease

Headache, diarrhoea, flatulence, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash/pruritus, alopecia, and allergy, infection, and chest pain.

• Increased AUC for norethindrone and ethinyl estradiol.
• Co-admin with antacid suspensions and colestipol decreased atorvastatin levels.
• Increased risk of rhabdomyolysis when used concurently with fibrates.
• Concomitant multiple doses of digoxin and atorvastatin increased steady-state digoxin levels. 

Hypersensitivity, liver disease, porphyria, pregnancy, unexplained persistent elevations of serum transaminase and lactation.

Store it at room temperature

Molecular weight

557.6319

Molecular formula

C33H34FN2O5

CAS number

134523-00-5

Precautions

• Hypothyroidism should be properly managed prior to starting statin therapy.
• History of liver disease.
• Patients who consume substantial quantities of alcohol.
• Patients with risk factors for myopathy or rhabdomyolysis.
• Children <10 years.